Minneapolis, USA-based life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities, Bio-Techne entered into an agreement to acquire Lunaphore Technologies SA, a Switzerland-based life sciences company developing technology to enable spatial biology in the laboratory. The company announced the acquisition on June 23, 2023. However, it did not disclose the amount of the deal.
Purpose of acquisition by Bio-Techne
Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024.
Earlier, the companies announced a strategic partnership to develop the first fully automated spatial multi-omic workflow. This fully automated multi omics solution intends to utilize Lunaphore’s COMET™ instrument and SPYRE™ antibody panels as well as Bio-Techne’s RNAscope HiPlex technology to enable simultaneous hyperflex detection of protein and RNA biomarkers on the same slide at single-cell resolution.
What the Bio-Techne official has to comment
Chuck Kummeth, President and Chief Executive Officer of Bio-Techne, said, “Lunaphore is very complementary to Bio-Techne’s leading spatial biology franchise, as COMET™ delivers an automation platform for our RNAscope assays, and we leverage our global commercial team to penetrate this rapidly growing market. We also see additional synergies with our leading portfolio of antibodies and other products. Lunaphore is seeing strong initial traction with its COMET™ instrument, as this fully integrated, fully automated spatial biology system delivers the end-to-end automation that is in high demand from translational researchers. We anticipate COMET™ to play an important role as spatial biology gains traction in clinical applications. We are excited to welcome Lunaphore’s talented team, instrument portfolio, and technology to Bio-Techne.”
What Lunaphore Technologies has to say
Dr Ata Tuna Ciftlik, Chief Executive Officer of Lunaphore, further said, “We are truly excited to be joining Bio-Techne and combining capabilities to lead the Spatial Biology market. Our shared vision of tackling the translational and clinical research market while using our complementary best-in-class spatial proteomics and transcriptomics products is going to make a great impact on our customers in advancing research. In addition, Bio-Techne’s global reach and commercial and operational excellence will enable Lunaphore to accelerate its penetration into the high-growth spatial biology market. We are now joining forces to be the largest spatial biology player.”
About Bio-Techne
In 1981, Founder Roger C. Lucas, PhD launched Bio-Techne. The company is a leading developer and manufacturer of high-quality purified proteins and reagent solutions. The soutions include cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions, including T-Cell activation technologies.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
